Cantor Fitzgerald raised target for Amgen stock to USD 440

Published on 10/13/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald set a USD 440 target from USD 400 on October 8, 2026. Amgen stock was EUR 376.93 on October 13, 2026.

Key points in brief

Cantor Fitzgerald raised its Amgen target to USD 440 from USD 400 on October 8, 2026, while keeping a Neutral rating.
Amgen's second-quarter 2026 revenue reached USD 10.05 billion, and full-year revenue guidance stands at USD 38.2 billion to USD 39.4 billion.
The Lang & Schwarz price was EUR 376.93 on October 13, 2026 at 11:36 a.m. CEST.
Amgen is scheduled to report third-quarter 2026 results on November 3, 2026, according to MarketBeat.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was trading at EUR 376.93 at Lang & Schwarz on October 13, 2026 at 11:36 a.m. CEST. On October 8, 2026, Cantor Fitzgerald raised its target to USD 440 from USD 400 while maintaining a Neutral rating, as Investing.com reported.

Three milestones shape the story

On August 4, 2026, Amgen reported second-quarter revenue of USD 10.05 billion and adjusted earnings per share of USD 6.29 against consensus of USD 5.62, according to the Yahoo Finance transcript. The earnings call also cited USD 3.5 billion of free cash flow in the second quarter.

On September 22, 2026, Amgen said the phase 3 OASIZ 301 study of dazodalibep met its primary endpoint at Week 48. The trial enrolled approximately 621 patients, with improvements in disease activity observed from Week 4 through Week 48, according to Amgen.

On October 8, 2026, Cantor Fitzgerald's USD 440 target replaced its USD 400 target, a USD 40 increase, while the rating stayed Neutral. The same report said commercial execution and the durability of momentum ahead of MariTide data expected in the first half of 2027 remain central to the assessment.

What does the pipeline mean for growth?

The second-quarter figures show both scale and concentration. Amgen's six key growth drivers grew 26 percent year over year and represented nearly 70 percent of second-quarter product sales, according to the Yahoo Finance transcript. Repatha sales rose 37 percent to USD 953 million, while UPLIZNA sales increased 90 percent to USD 335 million.

The counterweight is visible in the mature portfolio. Prolia and XGEVA together generated USD 1.1 billion in second-quarter sales, down 33 percent year over year as biosimilar competition increased. That decline makes the pipeline milestones financially relevant, rather than merely clinical.

Results date and trading level

Amgen's full-year 2026 revenue outlook is USD 38.2 billion to USD 39.4 billion, while adjusted earnings per share guidance is USD 22.30 to USD 23.50, according to the Q2 earnings transcript. The company also expects a non-GAAP operating margin of 45 percent to 46 percent for 2026.

MarketBeat lists November 3, 2026 as the estimated date for Amgen's third-quarter 2026 results, with the conference call scheduled for 4:30 p.m. ET. The company is listed on Nasdaq under ticker AMGN, with a USD 288.00 to USD 447.03 52-week range and a market capitalization of USD 225.4 billion as of October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.